HLN Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the As…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading European equities traded in the US as American depositary receipts were lower on Tuesday morning, de | ||
 LCUT vs. HLN: Which Stock Is the Better Value Option? LCUT vs. HLN: Which Stock Is the Better Value Option? | ||
J.P. Morgan flags negative catalyst at Haleon on weak sales momentum Investing.com -- J.P. Morgan put “underweight” rated Haleon on negative Catalyst Watch ahead of its Oct. 29 results, saying third-quarter like-for-like sales growth is tracking at 3%, leaving the consumer health company at the bottom of its 3%-5% guidance range for a second straight year. | ||
 Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook Haleon PLC (LSE:HLN, NYSE:HLN), the consumer healthcare group, is expected to reduce its 2026 organic sales growth guidance after UBS forecast a subdued third quarter and limited visibility over the cough and cold season. UBS expects Haleon to report organic sales growth of 3.1% for the three... | ||
 3 British AI Stocks With Revenue Up To £61 Billion Rising UK borrowing costs, highlighted by the recent jump in 10 year gilt yields ahead of the next budget, are forcing investors to think harder about where future growth could come from. That is one reason artificial intelligence in healthcare is getting more attention. This piece looks at three UK focused AI healthcare stocks from our screener that aim to tap into this shift and explains what each one offers. The three stocks covered below are just a sample, and the full screen surfaced 5... | ||
 Haleon is Buying Better Shelf Space, Can the Visibility Help it Against Procter & Gamble and Colgate-Palmolive? Haleon plc (NYSE:HLN) is trying to win the US consumer-health market one shelf at a time. The Sensodyne and Advil owner has secured more prominent positions at Walmart Inc. (NYSE:WMT), Target Corporation (NYSE:TGT), and other major retailers by offering improved commercial terms, including lower prices, stronger promotions, new products, and exclusivity. READ ALSO: Keurig Dr […] | ||
 Deutsche Bank stays bearish on Haleon as growth headwinds mount Deutsche Bank has reiterated its 'sell' rating on Haleon PLC (LSE:HLN, NYSE:HLN), warning that the consumer health group faces persistent pressure on growth even as it heads into the cold and flu season. The broker kept a 320p price target on the FTSE 100 company, whose brands include... | ||
Haleon Turns to Weight-Loss Drug Users for its Next U.S. Growth Opportunity Haleon plc (NYSE:HLN) is finding a new growth opportunity in the expanding U.S. population using GLP-1 weight-loss drugs such as Wegovy and Zepbound. According to Reuters, the company has been placing products that can address GLP-1-related side effects in both its normal store locations and dedicated GLP-1 sections at CVS. That strategy has produced an […] | ||
 A drugmaker is gaining from the side effects of weight-loss drugs The consumer health company’s GLP-1 shelf strategy at CVS is paying off, and bigger retailers could follow. | ||
 Tums-Maker’s Sales Grow as Weight-Loss Drug Users Grapple With Uncomfortable Side Effects Up to 70% of GLP-1 patients experience gastrointestinal issues including nausea, vomiting, diarrhea, and constipation, per one study. | ||
 Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs By Richa Naidu LONDON, Sept 16 (Reuters) - Consumer health company Haleon has achieved growing sales of products to counter side-effects of weight-loss drugs in the United States, the company said, | ||
 Walmart and Target’s Shelves are Becoming a Battleground for Budget-Conscious Shoppers Shelf placement is becoming an increasingly important competitive weapon at Walmart Inc. (NYSE:WMT) and Target Corporation (NYSE:TGT). Haleon, the company behind Sensodyne, Advil, and Centrum, has negotiated more prominent positions at the two retailers by offering lower prices, stronger promotions, exclusive products, and other improved commercial terms. The strategy appears to be benefiting Haleon, whose […] | ||
 LCUT or HLN: Which Is the Better Value Stock Right Now? LCUT vs. HLN: Which Stock Is the Better Value Option? | ||
 Deutsche Bank expects European consumer staples to underperform as structural pressures mount European consumer staples stocks are trading at 18-year lows relative to the broader market, yet Deutsche Bank expects the sector to continue to underperform as consumer spending fails to keep pace with nominal economic growth. Analyst Tom Sykes said the bank has repeatedly tested the... | ||
 Haleon And 2 British AI Healthcare Stocks To Watch With UK gilt yields responding to shifting Bank of England expectations, investors are rethinking where dependable long term growth could come from. Healthcare companies using artificial intelligence to improve diagnosis and treatment sit at the crossroads of technology and essential services, which can matter when borrowing costs and inflation concerns move in and out of focus. This article highlights three UK listed AI healthcare stocks from our screener to put on your radar. The stocks... | ||
Sector Update: Healthcare Stocks Edge Higher Late Afternoon Healthcare stocks were slightly higher late Thursday afternoon, with the NYSE Healthcare Index incre | ||
 Guinness owner drops responsible drinking targets from boss’s bonus Guinness maker Diageo has stripped responsible drinking and diversity targets from bosses’ bonuses after Sir Dave Lewis launched a radical turnaround of the struggling beverages giant. | ||
 Reckitt Benckiser shares rise over 4% as JP Morgan upgrades to 'overweight' Shares in Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer goods company behind Dettol and Nurofen, rose over 4% on Tuesday as investors digested a legal win for its Mead Johnson unit and a JP Morgan upgrade to overweight. The upgrade came in a wider note on European consumer... | ||
 Futura Medical advances Eroxon pipeline as it reshapes US commercial strategy Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has passed a series of operational milestones across its sexual health portfolio as it repositions for growth following a strategic review. The AIM-listed group behind Eroxon, the over-the-counter erectile dysfunction gel, appointed Market... | ||
Papela joins Blister Pack Collective as first converter partner Papela will offer converter know-how for work on blister packaging aimed at nutraceutical, supplement and healthcare-linked uses. | ||
 LCUT vs. HLN: Which Stock Is the Better Value Option? LCUT vs. HLN: Which Stock Is the Better Value Option? | ||
 Jefferies raises Haleon price target to 410p on margin strength Jefferies has raised its price target for Haleon (Haleon PLC (LSE:HLN, NYSE:HLN), the consumer health company behind Sensodyne and Advil, to 410p from 400p, maintaining its Buy rating. The broker highlighted a 70 basis point margin beat in the first half of the year, though it warned this... | ||
Procter & Gamble to acquire Thorne for $3.8 billion, CEO says Investing.com -- Procter & Gamble Co. reached an agreement to acquire supplement maker Thorne for $3.8 billion, with the deal set to be announced later today. | ||
 ACCO vs. HLN: Which Stock Is the Better Value Option? ACCO vs. HLN: Which Stock Is the Better Value Option? | ||
Haleon PLC (HLN) (H1 2026) Earnings Call Highlights: Organic Growth Improves, North America ... Haleon PLC (HLN) delivers sequential organic sales growth of 3.1% in Q2, with strong North America and emerging market performance offsetting persistent respiratory weakness. | ||
 Sensodyne maker Haleon slips as sales growth concerns overshadow profit beat July 30 (Reuters) - Sluggish European demand and weak respiratory sales raised doubts on Thursday about whether Haleon can meet its sales targets, sending shares in the consumer health company lower despite better-than-expected first-half profit. The British maker of Theraflu and Flonase cold medicines and Sensodyne toothpaste reported first-half organic revenue growth of 2. | ||
 Haleon H1 Earnings Call Highlights Haleon (NYSE:HLN) said its second-quarter organic sales growth accelerated to 3.1% from 2.2% in the first quarter, supported by improved execution in North America, continued growth in emerging markets and a stronger contribution from pain relief and oral health products. Chief Executive Officer Br | ||
 Haleon slides as quality of growth questioned Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 2.9% to 368.7p after the consumer healthcare group reported improving second-quarter sales but left its full-year guidance unchanged. Organic revenue increased 3.1% in the second quarter, split between 1.7% from pricing and 1.4% from volumes and... | ||
 Is Kenvue Stock Attractive After Margin Gains and Deal Uncertainty KVUE's margin gains and stronger cash flow boost its appeal, but slow organic growth, debt and deal uncertainty keep the outlook balanced. | ||
Kenvue Benefits From Consumer Health Trends and Margin Expansion Kenvue's beauty momentum, margin expansion and stronger cash flow support its outlook as uneven demand and deal uncertainty temper visibility. | ||
 Haleon (HLN) Partners with Microsoft (MSFT) to Advance Digital and AI Capabilities Haleon (NYSE:HLN) is one of the best up and coming stocks to invest in right now. On June 1, Haleon announced a five-year collaboration with Microsoft (NASDAQ:MSFT) to scale its digital, data, and AI capabilities. This partnership aims to accelerate the company’s global “Win as One” strategy by integrating Microsoft’s cloud and AI tools into […] | ||
 Haleon Signs a Five-Year Agreement With Microsoft (MSFT) to Deploy Agentic AI Across Its Global Operations Microsoft Corporation (NASDAQ:MSFT) is one of the top stocks to buy according to Whale Rock Capital Management. On June 29, Haleon, a consumer health company, announced a new five-year collaboration with Microsoft Corporation (NASDAQ:MSFT) to expand the use of cloud, data, and artificial intelligence tools across Haleon’s global operations. Haleon said the deal builds on […] | ||